SASKATOON, Nov. 5, 2013 /CNW/ - CanniMed Ltd., the first producer to
have received a license under the new Marihuana for Medical Purposes Regulations (MMPR), released their first shipment of medical marijuana to Canadian
"Since receiving our license on September 19th, our team has been
working tirelessly to ensure that patients receive their trusted
medication as early as possible," said Brent Zettl, CEO, CanniMed Ltd.
"Continuity of care is critical for patients and the transition to the
new program has been a challenge for some. We are committed to
providing our patients with a higher level of service than they
previously received from Health Canada, with the medication that they
are comfortable with after years of use."
CanniMed has also developed a new customer call centre to provide
patients and physicians with support.
Why Medical Marijuana?
Within the human body, the endocannabinoid system influences a wide
range of physiological processes, including immune function,
inflammation, appetite, metabolism, cardiovascular function, digestion,
pain, reproduction, memory, sleep, stress regulation and mood.
Medical marijuana, or cannabis, which acts on the endocannabinoid
system, has the potential for broad therapeutic uses. Within the
cannabis plant, the main active ingredient is
delta-9-tetrahydrocannabinol, or THC, and is responsible for the
psychoactive effects of cannabis.
In a published study involving patients suffering from post-traumatic or
postsurgical neuropathic pain, a single inhalation of 25 mg of cannabis
with 9.4 per cent THC, statistically reduced the intensity of pain,
improved sleep and was well tolerated.i
Cannabis also contains other active ingredients, including cannabidiol
or CBD. Pre-clinical studies suggest that CBD, which is not
psychoactive, has anti-inflammatory, analgesic, anti-nausea,
anti-emetic and anti-psychotic effects.
As an example, researchers are beginning to study the use of high CBD
cannabis on patients suffering from Posttraumatic Stress Disorder
(PTSD), a condition that physicians find very challenging to treat with
the current medical therapies available.
"Since every patient has a unique medical need, the largest benefit of
the new MMPR program is that it allows licensed producers to offer
healthcare professionals and their patients with more choices than
through the previous system," added Mr. Zettl. "We are currently
shipping CanniMed 12•0 (12.5% THC & less than 0.5% CBD) and CanniMed 17•1 (17% THC and 0.7% CBD). In early 2014 two additional products will be
added, including a line with higher CBD, CanniMed 9•9 (9% THC and 9% CBD). Research into the discovery of new product lines
is ongoing; we will continue to make new products available to patients
CanniMed Ltd. was the first producer to be licensed under the new Marihuana for Medical Purposes Regulations. Our pharmaceutical-grade marijuana is produced under Good
Manufacturing Practices (GMP) regulations, the criteria used to
manufacture all pharmaceuticals in Canada.
We are committed to standardizing care by taking a leadership role in
closing the gap between the anecdotal benefit of medical marijuana and
evidenced-based scientific research. Our goal is to provide improved
access for Canadians who rely on medical marijuana through scientific
collaborations with external partners including academic institutions
and healthcare professionals.
Our primary focus is patient safety by strictly following a 281 point
quality control process.
i Ware, M. A., Wang, T., Shapiro, S., Robinson, A. and others. (2010) Smoked Cannabis for Chronic Pain: a Randomized Controlled Trial. Canadian Medical Association Journal (CMAJ). 182:E694-E701.
Image with caption: "CanniMed logo (CNW Group/Prairie Plant Systems Inc.)". Image available at: http://photos.newswire.ca/images/download/20131105_C9990_PHOTO_EN_32929.jpg
SOURCE: Prairie Plant Systems Inc.
For further information:
For more information please visit www.cannimed.ca or contact:
Marketing & Communications Coordinator
Prairie Plant Systems Inc.
Dara Willis Communications